Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Localize and Controlled co-delivery of AuNPs conjugated siRNA by Cationic Shear-thinning Gel Matrix for Treatment of Arthritis (DesiRTA)

Descrizione del progetto

Nanoterapia mirata per un sollievo duraturo dall’artrite

L’artrite è una patologia comune che causa dolore cronico, rigidità e limitazione dei movimenti. Sebbene i farmaci antinfiammatori e steroidi possano alleviare i sintomi, questi trattamenti comportano spesso effetti collaterali a lungo termine e non arrestano la progressione della malattia. Ciò implica che molti pazienti devono assumere farmaci per tutta la vita, con conseguenti rischi per la salute e oneri finanziari. Il progetto DesiRTA, finanziato dall’UE, mira a sviluppare una nuova terapia che agisca sulle cause alla base dell’artrite. Ricercatori in Irlanda e Portogallo stanno sviluppando un sistema basato su nanoparticelle d’oro per veicolare molecole di silenziamento genico direttamente alle articolazioni infiammate, offrendo un’alternativa controllata e priva di effetti collaterali per un sollievo duraturo.

Obiettivo

Arthritis is a common metabolic and immune associate disease that causes chronic pain and inflammation in a joint. Approximately
312 million people are affected by arthritis globally. It affects adults of all ages, both sexes, and all races and ethnicities, but the
prevalence in women is more than in men. Professional organizations have established many arthritis treatment regimens and
management guidelines; in those nonsteroidal anti-inflammatory drugs (NSAIDs), steroids and biologicals are the main ones. These are
effective against the disease aggressiveness and pain up to some extent, but the problem is this treatment is only symptomatic and
requires taking them lifelong; in that case, these drugs cause severe health problems and again increase the economic burden. For
these reasons, we need to develop a therapeutic technique and medication that can eliminate the symptom and causes of the disease
forever and prevent the ever-increasing number of patients worldwide. DesiTRA projects are an effort in the same vein to develop an
effective therapeutic alternative for arthritis that will avoid the aggravation of disease symptoms and cause of the disease together,
without causing any health-associated side effects. In this, mainly gold nanoparticle (AuNPs) conjugated siRNA will be delivered at the
disease site locally. Modified polysaccharides will increase the stability and release rate of AuNPs-siRNA, and these assemblies will be
delivered very controlled and precisely through a synovial fluid mimicking the shear-thinning hydrogel system. The ambitious
project will be conducted at two different groups and laboratories in Ireland and Portugal. The project involves experienced
researchers of other but related areas that will allow applicants to work in multidisciplinary aspects. The prestigious fellowship will
provide a plate form of renowned subject experts, and exposure to international collaborators will provide a unique opportunity to
grow as a true researcher

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2022-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

UNIVERSITY OF LIMERICK
Contributo netto dell'UE
€ 199 694,40
Indirizzo
NATIONAL TECHNOLOGICAL PARK, PLASSEY
- Limerick
Irlanda
Regione
Ireland Southern Mid-West
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Partner (1)